Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma

The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bulletin of experimental biology and medicine 2018-12, Vol.166 (2), p.253-256
Hauptverfasser:	Braga, E. A., Loginov, V. I., Filippova, E. A., Burdennyi, A. M., Pronina, I. V., Kazubskaya, T. P., Khodyrev, D. S., Utkin, D. O., Kushlinskii, D. N., Adamyan, L. V., Kuslinskii, N. E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Cell Biology CpG Islands Disease Progression DNA Methylation Epigenesis, Genetic Female Gene Expression Regulation, Neoplastic Humans Internal Medicine Laboratory Medicine Lymphatic Metastasis Metastases MicroRNAs MicroRNAs - genetics MicroRNAs - metabolism Middle Aged miRNA Neoplasm Staging Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - diagnosis Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Pathology Sensitivity and Specificity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The study was designed to determine genes of microRNAs hypermethylated in malignant ovarian tumors and to select new diagnostic and prognostic markers of the disease and effective system of markers. Using methyl-specific PCR and a representative sample of 54 ovarian cancer specimens, we determined 5 microRNA genes ( MIR-34b/c , MIR-9-1 , MIR-124-3 , MIR-129-2 , and MIR-107 ) hypermethylated in the majority of tumor samples in comparison with paired samples of histologically unchanged tissue (48-57% vs . 4-19%, p
ISSN:	0007-4888 1573-8221
DOI:	10.1007/s10517-018-4326-0